Viatris recall puts product quality and investor attention in focus

Viatris (VTRS) has initiated a voluntary Class II recall of a specific Xanax XR lot in the US, after the tablets failed dissolution specifications. This development is drawing attention to the company’s quality controls and potential regulatory implications.

The recall comes at a time when Viatris shares trade at $14.97, with a 30-day share price return of 10.81% and a 1-year total shareholder return of 84.98%. This suggests recent momentum has been strong even as product quality and regulatory risk stay in focus.

If events like this have you comparing risk and reward across healthcare names, it could be a good moment to scan for other opportunities in 32 healthcare AI stocks

With Viatris reporting US$14.3b in revenue, a loss of US$3.5b and an intrinsic value estimate that is 73% above the current US$14.97 share price, investors have to ask: is this a genuine mispricing, or is the market already baking in future growth potential?

Most Popular Narrative: 61.9% Undervalued

According to the most followed narrative, Viatris has a fair value of $39.24, which sits well above the recent $14.97 share price and frames a very large valuation gap.

The early years were tough: many Upjohn products were in natural decline, the generics market is brutally competitive, and the merger came with a heavy debt load. Investors saw a company that needed to shrink rather than grow, and the stock lagged for years. But beneath the surface, something different was happening. Viatris continued to generate massive cash flows and used them to reduce debt, stabilize margins, and invest selectively in new areas such as biosimilars and cardiovascular treatments.

This narrative leans heavily on cash flow strength, future profitability and improving margins to justify that higher value. Curious which specific assumptions do the heavy lifting here?

According to Adje1959, the fair value rests on Viatris shifting from current losses of $3.5b to a healthier profit profile, while earnings growth expectations and a richer future earnings multiple support the gap between $14.97 and $39.24. The narrative also leans on a discount rate of 6.956% to translate those projected cash flows into today’s dollars.

Result: Fair Value of $39.24 (UNDERVALUED)

However, this hinges on Viatris lifting profits from a US$3.5b loss and maintaining product quality, as recalls or regulatory setbacks could quickly challenge the thesis.

Next Steps

With strong opinions forming on both the risks and rewards here, it makes sense to move quickly, review the underlying numbers yourself, and weigh up the 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Viatris has your attention, do not stop here. Broaden your watchlist with other opportunities that match your goals before the next move passes you by.

• Spot potential value plays early by scanning 53 high quality undervalued stocks that pair solid fundamentals with prices that may not fully reflect their financial profile.
• Strengthen your income focus by checking out 12 dividend fortresses that combine higher yields with a focus on consistent shareholder payouts.
• Prioritise resilience by reviewing 73 resilient stocks with low risk scores that aim for steadier profiles and fewer unpleasant surprises.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.